Tempest Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies, particularly in the area of immuno-oncology. The company is advancing its lead asset, TPST-1120, a dual-action immunotherapy targeting both tumor cells and the tumor microenvironment, which distinguishes it from competitors in the oncology space.
Tempest Therapeutics primarily generates revenue through strategic partnerships with larger pharmaceutical firms for the development and commercialization of its drug candidates. The company has a strong focus on immunotherapy, which provides it with a competitive advantage in a rapidly evolving market. Its unique approach to targeting both tumor cells and the tumor microenvironment may allow for improved efficacy and patient outcomes.
Clinical trial results for TPST-1120 and other pipeline candidates
Partnership announcements with larger pharmaceutical companies
Regulatory approvals or setbacks from the FDA
Market sentiment around immuno-oncology therapies
Regulatory changes that could impact drug approval processes
Technological disruption in cancer treatment methodologies
Emerging therapies from larger biotech firms that could overshadow Tempest's offerings
Rapid advancements in personalized medicine that may render current approaches less effective
High debt-to-equity ratio (9.55) indicating potential liquidity issues
Negative cash flow and lack of revenue could limit operational flexibility
low - as a biotech firm, Tempest Therapeutics is less sensitive to economic cycles; its performance is more closely tied to clinical outcomes and regulatory approvals than to GDP fluctuations.
Interest rates can impact the company's ability to raise funds for R&D, as higher rates may increase the cost of capital. However, as a biotech firm, it is less sensitive to interest rate changes compared to more capital-intensive industries.
minimal - the company is not heavily reliant on credit markets, given its current lack of revenue.
growth - investors looking for high-risk, high-reward opportunities in the biotech sector.
high - the stock has shown significant volatility, with a 1-year return of -80.9%.